Reviewer_2_v.1 – Supplemental material for Impact of baseline COPD symptom severity on the benefit from dual versus mono-bronchodilators: an analysis of the EMAX randomised controlled trial

Vogelmeier, Claus F.; Kerwin, Edward M.; Bjermer, Leif H.; Tombs, Lee; Jones, Paul W.; Boucot, Isabelle H.; Naya, Ian P.; Lipson, David A.; Compton, Chris; Barnes, Neil; Maltais, François

doi:10.25384/SAGE.13221349.v1

Reviewer_2_v.1.pdf (72.25 kB)

Reviewer_2_v.1 – Supplemental material for Impact of baseline COPD symptom severity on the benefit from dual versus mono-bronchodilators: an analysis of the EMAX randomised controlled trial

journal contribution

posted on 2020-11-11, 13:07 authored by Claus F. Vogelmeier, Edward M. Kerwin, Leif H. Bjermer, Lee Tombs, Paul W. Jones, Isabelle H. Boucot, Ian P. Naya, David A. Lipson, Chris Compton, Neil Barnes, François Maltais

Supplemental material, Reviewer_2_v.1 for Impact of baseline COPD symptom severity on the benefit from dual versus mono-bronchodilators: an analysis of the EMAX randomised controlled trial by Claus F. Vogelmeier, Edward M. Kerwin, Leif H. Bjermer, Lee Tombs, Paul W. Jones, Isabelle H. Boucot, Ian P. Naya, David A. Lipson, Chris Compton, Neil Barnes and François Maltais in Therapeutic Advances in Respiratory Disease